The Knowledge Group: Patent Acquisitions - When Are They HSR Reportable?

The Knowledge Group: Patent Acquisitions - When Are They HSR Reportable?

Speaking Engagement

The Knowledge Group has developed a panel of key thought Leaders and practitioners to help companies understand the Hart-Scott-Rodino (HSR) rules for patent acquisitions, including the new rules of the Federal Trade Commission (FTC) for exclusive pharmaceutical patent licenses. The program will cover the most significant topics involved along with a Q&A panel to whom the attendees' questions will be addressed.

Topics discussed will include:

  • The HSR Act: An Overview
  • The "Size of Transaction" Test
  • The "Size of Parties" Test
  • Patents as "Assets" Whose Acquisition May Be Reportable
  • Patent Acquisitions in the Pharmaceutical Industry: What Is New and What Is Not under the Amended Rules?
  • Impact and Key Risks
  • Compliance Issues
  • Up-to-Minute Regulatory Updates

WilmerHale Partner Hartmut Schneider is a featured speaker at this event.

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.